Revenue Showdown: Vertex Pharmaceuticals Incorporated vs Catalent, Inc.

Vertex vs Catalent: A Decade of Revenue Growth

__timestampCatalent, Inc.Vertex Pharmaceuticals Incorporated
Wednesday, January 1, 20141827700000580415000
Thursday, January 1, 201518308000001032336000
Friday, January 1, 201618481000001702177000
Sunday, January 1, 201720754000002488652000
Monday, January 1, 201824634000003047597000
Tuesday, January 1, 201925180000004162821000
Wednesday, January 1, 202030943000006205683000
Friday, January 1, 202139980000007574400000
Saturday, January 1, 202248280000008930700000
Sunday, January 1, 202342760000009869200000
Monday, January 1, 2024438100000011020100000
Loading chart...

Unleashing the power of data

Revenue Showdown: Vertex Pharmaceuticals vs Catalent, Inc.

In the competitive landscape of the pharmaceutical industry, revenue growth is a key indicator of success. Over the past decade, Vertex Pharmaceuticals Incorporated and Catalent, Inc. have been at the forefront of this financial race. Since 2014, Vertex has demonstrated a remarkable revenue growth trajectory, increasing its revenue by over 1,600% from 2014 to 2023. In contrast, Catalent has shown a steady growth of approximately 140% during the same period.

Vertex's revenue surge is particularly notable from 2019 onwards, where it consistently outpaced Catalent, reaching a peak in 2023. Catalent, while experiencing a dip in 2023, has maintained a strong presence with a 2022 revenue peak. The data highlights Vertex's aggressive growth strategy, while Catalent's consistent performance underscores its stability in the market. As we look to the future, the absence of 2024 data for Vertex leaves room for speculation on its continued dominance.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025